HSBC Downgrades Biogen to Reduce, Lowers Price Target to $143

Benzinga · 2d ago
HSBC analyst Rajesh Kumar downgrades Biogen (NASDAQ:BIIB) from Hold to Reduce and lowers the price target from $144 to $143.